ulixacaltamide

AssetAlso PRAX-944

T-type calcium channel blocker

Stage: Phase 3
Modality: Small molecule
Target: CACNA1G; 1
Indication: 1
Trial: 1
Developer

Indications

1

Essential tremor
Phase 3, Recruiting, NCT06087276, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners1
Trials1
Evidence for its targets1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source